Journal Article
. 2018 Aug;7(9).
doi: 10.3390/jcm7090245.

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Yu-Hsiang Huang 1 Pei-Yi Chu 2 Ji-Lin Chen 3 Chun-Teng Huang 4 Chia-Han Lee 5 Ka-Yi Lau 6 Wan-Lun Wang 7 Yu-Ling Wang 8 Pei-Ju Lien 9 Ling-Ming Tseng 10 Chun-Yu Liu 11 
Affiliations
  • PMID: 30154367
  •     41 References
  •     3 citations

Abstract

Adjuvant tamoxifen reduces the recurrence rate of estrogen receptor (ER)-positive breast cancer. Previous in vitro studies have suggested that tamoxifen can affect the cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A)/phosphorylation Akt (pAkt) signaling in ER-negative breast cancer cells. In addition to CIP2A, SET nuclear proto-oncogene (SET) oncoprotein is another intrinsic inhibitor of PP2A, participating in cancer progression. In the current study, we explored the clinical significance of SET, CIP2A, PP2A, and Akt in patients with ER-positive breast cancer receiving adjuvant tamoxifen. A total of 218 primary breast cancer patients receiving adjuvant tamoxifen with a median follow-up of 106 months were analyzed, of which 17 (7.8%) experienced recurrence or metastasis. In an immunohistochemical (IHC) stain, SET overexpression was independently associated with worse recurrence-free survival (RFS) (hazard ratio = 3.72, 95% confidence interval 1.26⁻10.94, p = 0.017). In silico analysis revealed mRNA expressions of SET, PPP2CA, and AKT1 significantly correlated with worse RFS. In vitro, SET overexpression reduced tamoxifen-induced antitumor effects and drove luciferase activity in an Estrogen receptor element (ERE)-dependent manner. In conclusion, SET is a prognostic biomarker in patients with primary ER-positive breast cancer receiving adjuvant tamoxifen and may contribute to the failure of the tamoxifen treatment by modulating the ER signaling. Our study warrants further investigation into the potential role of SET in ER-positive breast cancer.

Keywords: CIP2A; PP2A; SET; breast cancer; tamoxifen.

Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor.
S Saito, M Miyaji-Yamaguchi, T Shimoyama, K Nagata.
Biochem Biophys Res Commun, 1999 Jun 11; 259(2). PMID: 10362532
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Mitch Dowsett, Jack Cuzick, +16 authors, Richard Peto.
J Clin Oncol, 2009 Dec 02; 28(3). PMID: 19949017
Highly Cited.
Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Jukka Westermarck, William C Hahn.
Trends Mol Med, 2008 Mar 11; 14(4). PMID: 18329957
Highly Cited. Review.
Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
Shi-Wen Jiang, Siliang Xu, +4 authors, Jiayin Liu.
Clin Chim Acta, 2016 Nov 12; 464. PMID: 27836688
Review.
Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare.
Lee Cheng, Michael D Swartz, +5 authors, Sharon H Giordano.
Cancer Epidemiol Biomarkers Prev, 2012 Mar 20; 21(5). PMID: 22426147
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Po-Ming Chen, Pei-Yi Chu, +8 authors, Ling-Ming Tseng.
Hum Pathol, 2017 Jun 13; 66. PMID: 28603063
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Paolo Neviani, Ramasamy Santhanam, +14 authors, Danilo Perrotti.
Cancer Cell, 2005 Nov 16; 8(5). PMID: 16286244
Highly Cited.
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Hao Liu, Yixue Gu, +6 authors, Zhimin He.
Oncotarget, 2015 May 07; 6(17). PMID: 25945834    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Review.
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Nuria Ribelles, Lidia Perez-Villa, +11 authors, Emilio Alba.
Breast Cancer Res, 2013 Oct 24; 15(5). PMID: 24148581    Free PMC article.
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
J M Hall, D P McDonnell.
Endocrinology, 1999 Dec 01; 140(12). PMID: 10579320
Highly Cited.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.
Rachel J D Cossetti, Scott K Tyldesley, +2 authors, Karen A Gelmon.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422485
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Chun-Yu Liu, Man-Hsin Hung, +9 authors, Kuen-Feng Chen.
Breast Cancer Res, 2014 Sep 18; 16(5). PMID: 25228280    Free PMC article.
The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity.
Núria Canela, Aina Rodriguez-Vilarrupla, +4 authors, Oriol Bachs.
J Biol Chem, 2002 Oct 31; 278(2). PMID: 12407107
Protein phosphatase 2A: a target for anticancer therapy.
Danilo Perrotti, Paolo Neviani.
Lancet Oncol, 2013 May 04; 14(6). PMID: 23639323    Free PMC article.
Highly Cited. Review.
SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification.
Andréia M Leopoldino, Cristiane H Squarize, +7 authors, Carlos Curti.
Oral Oncol, 2012 Jun 29; 48(11). PMID: 22739068
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
Eun-Shin Lee, Wonshik Han, +9 authors, Eun Sook Lee.
BMC Cancer, 2016 Jul 09; 16. PMID: 27388210    Free PMC article.
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.
Parthasarathy Seshacharyulu, Poomy Pandey, Kaustubh Datta, Surinder K Batra.
Cancer Lett, 2013 Mar 05; 335(1). PMID: 23454242    Free PMC article.
Highly Cited. Review.
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Mahnaz Janghorban, Amy S Farrell, +6 authors, Rosalie C Sears.
Proc Natl Acad Sci U S A, 2014 Jun 14; 111(25). PMID: 24927563    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Otto Metzger-Filho, Zhuoxin Sun, +8 authors, Fatima Cardoso.
J Clin Oncol, 2013 Jul 31; 31(25). PMID: 23897954    Free PMC article.
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
CIP2A inhibits PP2A in human malignancies.
Melissa R Junttila, Pietri Puustinen, +17 authors, Jukka Westermarck.
Cell, 2007 Jul 17; 130(1). PMID: 17632056
Highly Cited.
Anti-estrogenic effects of conjugated linoleic acid through modulation of estrogen receptor phosphorylation.
Jingbo Liu, Neil Sidell.
Breast Cancer Res Treat, 2005 Nov 02; 94(2). PMID: 16261415
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
Stephen B Edge, Carolyn C Compton.
Ann Surg Oncol, 2010 Feb 25; 17(6). PMID: 20180029
Highly Cited.
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Raúl Rincón, Ion Cristóbal, +10 authors, Federico Rojo.
Oncotarget, 2015 Mar 03; 6(6). PMID: 25726524    Free PMC article.
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
A K Samanta, S N Chakraborty, +5 authors, R B Arlinghaus.
Oncogene, 2009 Feb 24; 28(14). PMID: 19234487    Free PMC article.
Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Weipeng Zhang, Jiangxia Cai, +6 authors, Yalin Dong.
Mol Med Rep, 2015 Mar 12; 12(1). PMID: 25760096
Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Ion Cristóbal, Raúl Rincón, +5 authors, Jesús García-Foncillas.
Clin Cancer Res, 2014 Nov 13; 21(2). PMID: 25388166
Status of adjuvant endocrine therapy for breast cancer.
Gaia Schiavon, Ian E Smith.
Breast Cancer Res, 2014 Jul 18; 16(2). PMID: 25032258    Free PMC article.
Review.
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.
Peter P Ruvolo.
BBA Clin, 2016 Aug 25; 6. PMID: 27556014    Free PMC article.
Highly Cited. Review.
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Man-Hsin Hung, Cheng-Yi Wang, +7 authors, Kuen-Feng Chen.
Oncotarget, 2015 Nov 18; 7(1). PMID: 26575017    Free PMC article.
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Chun-Yu Liu, Ling-Ming Tseng, +5 authors, Kuen-Feng Chen.
Breast Cancer Res, 2013 Aug 14; 15(4). PMID: 23938089    Free PMC article.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Anchit Khanna, John E Pimanda, Jukka Westermarck.
Cancer Res, 2013 Nov 10; 73(22). PMID: 24204027
Highly Cited. Review.
Protein phosphatase 2A inhibitors, I(1)(PP2A) and I(2)(PP2A), associate with and modify the substrate specificity of protein phosphatase 1.
Y Katayose, M Li, +2 authors, Z Damuni.
J Biol Chem, 2000 Mar 29; 275(13). PMID: 10734057
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Györffy, Andras Lanczky, +4 authors, Zoltan Szallasi.
Breast Cancer Res Treat, 2009 Dec 19; 123(3). PMID: 20020197
Highly Cited.
Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression.
Deepika Raman, Shazib Pervaiz.
Redox Biol, 2019 Jan 29; 27. PMID: 30686777    Free PMC article.
Review.
Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Tzu-Ting Huang, Ling-Ming Tseng, +12 authors, Chun-Yu Liu.
EBioMedicine, 2020 Apr 09; 54. PMID: 32268268    Free PMC article.
PP2A-B55 Holoenzyme Regulation and Cancer.
Perrine Goguet-Rubio, Priya Amin, +6 authors, Anna Castro.
Biomolecules, 2020 Dec 04; 10(11). PMID: 33266510    Free PMC article.
Review.